The Requirements of Managing Phase I Clinical Trials Risks: The British and Italian Case Studies

• Main Authors: Davide Di Tonno (Author), Laura Martena (Author), Manuela Taurisano (Author), Caterina Perlin (Author), Anna Chiara Loiacono (Author), Stefano Lagravinese (Author), Santo Marsigliante (Author), Michele Maffia (Author), Susanna Esposito (Author), Gianluca Villa (Author), Giovanni Gori (Author), Leonardo Bray (Author), Alessandro Distante (Author), Alessandro Miani (Author), Prisco Piscitelli (Author), Alberto Argentiero (Author)
• Format: Book
• Published: MDPI AG, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Phase I clinical trials represent a critical point in drug development because the investigational medicinal product is being tested in humans for the first time. For this reason, it is essential to evaluate and identify the Maximum Tolerated Dose (MTD) and the safety of the new compound. To mitigat...